Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease

Experimental and Therapeutic Medicine

Volumn 4, Issue 6, 2012, Pages 1051-1056

  Wang, Sheng Lan ^a   Wang, Zhi Rong ^a   Yang, Chang Qing ^a  

^a TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

Author keywords

Antibiotic therapy; Crohn's disease; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; BUDESONIDE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; ETHAMBUTOL; HYDROCORTISONE; INFLIXIMAB; MESALAZINE; METRONIDAZOLE; PLACEBO; PREDNISONE; RIFAMPICIN; RIFAXIMIN; SALAZOSULFAPYRIDINE; SULFAMETHOXAZOLE; TETRACYCLINE; TOBRAMYCIN;

ANTIBIOTIC THERAPY; CONFIDENCE INTERVAL; CROHN DISEASE; DRUG EFFICACY; EVALUATION; HUMAN; MEDLINE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 84867282079     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.718     Document Type: Review

References (32)

1. Sartor RB: Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633, 2004.
2. Duchman R, Kaiser I, Hermann E, et al: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 102: 448-455, 1995.
3. Podolsky DK: Inflammatory bowel disease. N Engl J Med 347: 417-429, 2002.
4. Prantera C and Scribano ML: Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. Curr Opin Gastroenterol 25: 329-333, 2009.
5. Sandborn WJ and Feagan BG: Review article: mild to moderate Crohn's disease - defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 18: 263-277, 2003.
6. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N and Kelly M: Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 32: 1071-1075, 1991.
7. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, et al: Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 123: 33-40, 2002.
8. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F and Cottone M: Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 23: 1117-1125, 2006.
9. Arnold GL, Beaves MR, Pryjdun VO and Mook WJ: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 8: 10-15, 2002.
10. West RL, van der Woude CJ, Hansen BE, et al: Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a doubleblind placebo-controlled study. Aliment Pharmacol Ther 20: 1329-1336, 2004
11. Leiper K, Martin K, Ellis A, et al: Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 27: 1233-1239, 2008.
12. Goodgame RW, Kimball K, Akram S, Ike E, Ou CN, Sutton F and Graham D: Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 15: 1861-1866, 2001.
13. Blichfeldt P, Blomhoff JP, Myhre E and Gjone E: Metronidazole in Crohn's disease. A double blind cross-over clinical trial. Scand J Gastroenterol 13: 123-127, 1978.
14. Ambrose NS, Allan RN, Keighley MR, et al: Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 28: 81-85, 1985.
15. Selby W, Pavli P, Crotty B, et al: Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132: 2313-2319, 2007.
16. Colombel JF, Lémann M, Cassagnou M, et al: A controlled trial comparing ciprofloxacin and mesalamine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol 94: 674-678, 1999.
17. Cho JH and Weaver CT: The genetics of inflammatory bowel disease. Gastroenterology 133: 1327-1339, 2007.
18. Kobayashi KS, Chamaillard M, Ogura Y, et al: Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307: 731-734, 2005.
19. Barnich N and Darfeuille-Michaud A: Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol 23: 16-20, 2007.
20. Issa M, Vijayapal A, Graham MB, et al: Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastronterol Hepatol 5: 345-351, 2007.
21. Greenbloom SL, Steinhart AH and Greenberg GR: Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol 12: 53-56, 1998.
22. Carter MJ, Lobo AJ, Travis SP, et al: Guidelines for the management of inflammatory bowel disease in adults. Gut 53 (Suppl 5): V1-V16, 2004.
23. Gilat T, Suissa A, Leichtman G, et al: A comparative study of metronidazole and sulfasalazine in active, not severe, ulcerative colitis. An Israeli multicenter trial. J Clin Gastroenterol 9: 415-417, 1987.
24. Chapman RW, Selby WS and Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27: 1210-1212, 1986.
25. Mantzaris GJ, Archavlis E, Christoforidis P, et al: A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 92: 454-456, 1997.
26. Mantzaris GJ, Petraki K, Archavlis E, et al: A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 36: 971-974, 2001.
27. Mantzaris GJ, Hatzis A, Kontogiannis P and Triadaphyllou G: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 89: 43-46, 1994.
28. Burke DA, Axon AT, Clayden SA, et al: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4: 123-129, 1990.
29. Gionchetti P, Rizzello F, Ferrieri A, et al: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroidtreatment: a double-blind, placebo-controlled trial. Dig Dis Sci 44: 1220-1221, 1999.
30. Turunen U, Färkkilä MA, Hakala K, et al: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 115: 1072-1078, 1998.
31. Ohkusa T, Nomura T, Terai T, et al: Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40: 1334-1342, 2005.
32. Ohkusa T, Kato K, Terao S, et al: Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol 105: 1820-1829, 2010.